Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2-3
|
pubmed:dateCreated |
1995-4-12
|
pubmed:abstractText |
A number of studies have demonstrated that potent anti-tumor immunity can be induced using cytokine gene transfer, a strategy termed transgenic immunotherapy. Our aim is to express cytokine genes in the vicinity of tumor cells, either by transducing tumor cells themselves, or by delivering cytokine-expressing endothelial cells to tumor sites. We compared the ability of cytokine-expressing tumor cells or endothelial cells to inhibit the tumorigenesis of MDA-MB-435 breast cancer cells in athymic nude mice. Retroviral vectors containing either human interleukin 2 (hIL-2) or interleukin 1 (hIL-1 alpha) were used to transduce MDA-MB-435 cells or human umbilical vein endothelial cells (HUVEC). Using a modified MTT bioassay and an ELISA specific for hIL-2, 43 of 70 MDA-MB-435 clones transduced with IL-2 were found to secrete between 100-800 units of IL-2/10(6) cells/24 hr. hIL-2 and hIL-1 alpha-transduced HUVEC secreted 40 ng/IL-2/10(6)/24 hr and 1.8 ng/10(6)/24 hr, respectively. To facilitate in vivo tracking of tumor cells, both nontransduced and IL-2-expressing MDA-MB-435 cells were genetically-marked with the E. coli lacZ gene and selected using flow cytometry. To study in vivo tumorigenicity, cells were injected into the mammary fat pad of athymic nude mice: (1) lacZ/MDA-MB-435 cells injected alone formed tumors in all animals; (2) IL-2-expressing lacZ/MDA-MB-435 cells did not form any tumors; (3) co-inoculation of MDA-MB-435/IL-2, or HUVEC/IL-2, or HUVEC/IL-1 alpha with lacZ/MDA-MB-435 cells prevented or delayed tumor growth.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0167-6806
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
31
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
349-56
|
pubmed:dateRevised |
2005-11-16
|
pubmed:meshHeading |
pubmed-meshheading:7881111-Animals,
pubmed-meshheading:7881111-Breast Neoplasms,
pubmed-meshheading:7881111-Cells, Cultured,
pubmed-meshheading:7881111-Endothelium, Vascular,
pubmed-meshheading:7881111-Gene Therapy,
pubmed-meshheading:7881111-Immunotherapy,
pubmed-meshheading:7881111-Interleukin-1,
pubmed-meshheading:7881111-Interleukin-2,
pubmed-meshheading:7881111-Killer Cells, Natural,
pubmed-meshheading:7881111-Mice,
pubmed-meshheading:7881111-Mice, Nude,
pubmed-meshheading:7881111-Mice, Transgenic,
pubmed-meshheading:7881111-Neoplasm Transplantation,
pubmed-meshheading:7881111-Recombinant Fusion Proteins,
pubmed-meshheading:7881111-Tumor Cells, Cultured
|
pubmed:year |
1994
|
pubmed:articleTitle |
Breast cancer gene therapy: transgenic immunotherapy.
|
pubmed:affiliation |
Department of Medicine (Division of Hematology), Georgetown University Medical Center, Washington, DC 20007.
|
pubmed:publicationType |
Journal Article,
Review
|